Essential role of HDAC6 in the regulation of PD-L1 in melanoma

Molecular Oncology
Lienlaf MVillagra A

Abstract

Histone deacetylases (HDACs), originally described as histone modifiers, have more recently been demonstrated to target a variety of other proteins unrelated to the chromatin environment. In this context, our present work demonstrates that the pharmacological or genetic abrogation of HDAC6 in primary melanoma samples and cell lines, down-regulates the expression of PD-L1, an important co-stimulatory molecule expressed in cancer cells, which activates the inhibitory regulatory pathway PD-1 in T-cells. Our data suggests that this novel mechanism of PD-L1 regulation is mainly mediated by the influence of HDAC6 over the recruitment and activation of STAT3. Additionally, we observed that selective HDAC6 inhibitors impairs tumor growth and reduce the in vivo expression of several inhibitory check-point molecules and other regulatory pathways involved in immunosurveillance. Most importantly, these results provide a key pre-clinical rationale and justification to further study isotype selective HDAC6 inhibitors as potential immuno-modulatory agents in cancer.

References

May 25, 2002·Nature·Charlotte HubbertTso-Pang Yao
Nov 8, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tomohide YamazakiHideo Yagita
Apr 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·P'ng Loke, James P Allison
Jun 30, 2005·Cancer Metastasis Reviews·Marcin KortylewskiHua Yu
May 9, 2006·Cancer Immunology, Immunotherapy : CII·Thomas B TomasiA Nazmul H Khan
Feb 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Peter J Murray
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Junzo HamanishiShingo Fujii
Sep 6, 2007·Genes & Development·Cyril BoyaultSaadi Khochbin
Jul 4, 2008·Cancer Control : Journal of the Moffitt Cancer Center·Jane L MessinaAdil I Daud
Jan 6, 2009·Biochemical and Biophysical Research Communications·Sumihito TogiTadashi Matsuda
Sep 12, 2009·The Journal of Biological Chemistry·Ana PalijanJohn H White
Oct 24, 2009·Nature Reviews. Cancer·Hua YuRichard Jove
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jul 20, 2010·Immunological Reviews·Loise M FranciscoArlene H Sharpe
Jan 27, 2011·European Journal of Immunology·Sabine J WölfleKlaus Heeg
Nov 23, 2011·Immunology and Cell Biology·Karrune V WoanAlejandro Villagra
Mar 16, 2012·The Journal of Investigative Dermatology·Masanobu SakaguchiChikako Nishigori
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Oct 26, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiaofeng JiangF Stephen Hodi
Jul 3, 2013·The British Journal of Dermatology·V Nikolaou, A J Stratigos
Sep 24, 2013·JAK-STAT·Greg M Delgoffe, Dario A A Vignali
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Aug 12, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Fengdong ChengEduardo M Sotomayor
Aug 15, 2014·Oncotarget·Michiel KroesenGosse J Adema
Oct 25, 2014·Nature Reviews. Cancer·Hua YuRichard Jove
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto

❮ Previous
Next ❯

Citations

Dec 21, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Henan ZhaoXiaohong Shu
May 10, 2019·International Journal of Molecular Sciences·Debarati BanikAlejandro Villagra
Nov 15, 2018·Blood Advances·Kamira MaharajJavier Pinilla-Ibarz
Sep 13, 2019·Science Translational Medicine·Ann LinJason M Sheltzer
May 31, 2018·Journal of Experimental & Clinical Cancer Research : CR·Feng XuChaoliu Dai
Aug 19, 2018·Cancer Immunology, Immunotherapy : CII·Yongyu Shi
Sep 5, 2018·Journal of Hematology & Oncology·Ting LiJilong Yang
Jan 30, 2019·International Journal of Cancer. Journal International Du Cancer·Yves DepetterOlivier De Wever
Jul 2, 2019·Frontiers in Immunology·Xiangfeng ShenZhi-Xiang Xu
Mar 14, 2020·Chemical Biology & Drug Design·Muhammad KalimJinbiao Zhan
Nov 16, 2018·Cancer Chemotherapy and Pharmacology·Ajimu KeremuXiaoguang Zou
Jul 7, 2020·Frontiers in Cell and Developmental Biology·Minjeong YeonDooil Jeoung
Feb 25, 2017·Journal of Translational Medicine·Gerardo BottiGiosuè Scognamiglio
Oct 10, 2020·European Journal of Medicinal Chemistry·Maurício T TavaresSida Shen
Nov 11, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Sravani PulyaBalaram Ghosh
Dec 17, 2020·Frontiers in Pharmacology·Maria Gracia-HernandezAlejandro Villagra
Mar 6, 2021·Bioorganic & Medicinal Chemistry·Maurício Temotheo TavaresRoberto Parise-Filho
Apr 3, 2021·Seminars in Cancer Biology·Jae Eun Lee, Mi-Young Kim
Jun 6, 2021·Journal of Experimental & Clinical Cancer Research : CR·Hao ZhangQuan Cheng
Oct 24, 2017·ACS Medicinal Chemistry Letters·Maurício T TavaresAlan P Kozikowski
Nov 5, 2019·Seminars in Immunology·Huiyuan Zhang, Vijay Kuchroo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis